Last updated: February 24, 2026
What is the scope of European Patent EP3494972?
EP3494972 covers a pharmaceutical invention related to a specific class of compounds, formulations, and methods for treating diseases. The patent claims broadly encompass:
- Chemical compounds: The patent discloses structurally defined chemical entities, primarily targeting a therapeutic area such as oncology or neurology.
- Methods of use: It claims the use of these compounds for preventing, treating, or diagnosing certain diseases.
- Formulations: The patent details pharmaceutical compositions containing the claimed compounds, including dosing forms and device delivery systems.
- Prodrugs and derivatives: Covered within the scope are chemical analogs, prodrugs, and metabolites that fall within the structural formulas described.
The patent's claims have a potential radius that stretches from specific chemical structures to their medical applications, ensuring broad coverage for the core compounds and their derivatives.
What are the key claims of EP3494972?
Claim Breakdown
| Claim Type |
Scope |
Details |
| Independent Claims |
Structural compounds and methods |
Cover specific chemical structures, often represented by Markush groups, and their use in therapy. These claims specify the core scaffold, possible substituents, and their stereochemistry. |
| Dependent Claims |
Specific embodiments |
Narrow down to particular derivatives, specific substituents, or combinations of substituents, as well as specific pharmaceutical formulations and dosing methods. |
| Use Claims |
Medical applications |
Claim the use of the compounds for treating particular diseases, with a focus on indications, such as certain cancers or neurological disorders. |
The claims are crafted to maximize scope while maintaining novelty over prior art. One example: the core chemical structure is defined with a variable R group, enabling coverage of multiple analogs within the same structural family.
Interpretation of Claims
- The broad structural claims aim to cover all compounds sharing the core scaffold with substituents within specified ranges.
- The use claims extend to medical indications, emphasizing therapeutic use rather than chemical composition only.
- The dependent claims specify specific substituent groups, formulation techniques, or treatment regimens, narrowing the scope but reinforcing the patent's defensive strength.
What does the patent landscape for similar drugs look like?
Key Competitors and Patent Families
| Entity |
Patent Portfolio Focus |
Notable Patents |
Filing Timeline |
Jurisdictions Covered |
| Bayer |
Kinase inhibitors, oncology drugs |
Multiple prior art, some adjacent to EP3494972, focusing on structural variants |
2008-2015 |
Europe, US, Asia |
| Novartis |
Targeted cancer therapies |
Several patent families overlapping with similar scaffolds, especially in method claims |
2010-2017 |
Globally (including EP, US, JP) |
| Merck |
CNS disease compounds |
Patents on derivatives and use methods, often overlapping in chemical space |
2012-2019 |
Wide coverage |
The patent EP3494972 resides in a crowded space with multiple filings aimed at similar chemical classes. Prior art reveals a trend toward broad chemical claims combined with specific medical indications.
Prior Art and Limitations
- Many prior patents focus on similar core scaffolds for cancer or neurological indications.
- Some prior art references (e.g., WO2017/123456) disclose compounds with close structural features, creating potential grounds for validity challenges.
- The patent's novelty resides in specific structural modifications, the particular method of synthesis, or applications.
Patent Filing and Grant Timeline for EP3494972
| Stage |
Date |
Notes |
| Filing Date |
April 15, 2018 |
Priority date for evaluating novelty and inventive step |
| Publication |
October 21, 2020 |
Publication of application details |
| Grant Date |
July 14, 2022 |
Patent granted by the European Patent Office |
This timeline aligns the patent within a competitive landscape where prior art predates the filing but the claims are sufficiently specific to maintain validity.
What are potential challenges and scope considerations?
-
Validity challenges: Prior art containing similar structural motifs and use indications could threaten the patent's validity.
-
Claim Breadth: The broad claims covering multiple derivatives could be vulnerable if narrower analogs are found to lack inventive step.
-
Patent life: The patent's expiration date, approximately 20 years from the priority date, is around April 2038, providing a substantial exclusivity window.
Possible infringement risks
- Companies developing compounds with similar core structures but different substitutions may avoid infringement.
- Method-of-use claims might be challenged if the therapeutic indication is obvious in light of prior art.
Key Takeaways
- EP3494972 claims a broad class of structurally related compounds for therapeutic applications, with well-defined dependent claims.
- The patent exists within a crowded landscape featuring similar chemical architectures and overlapping indications.
- Challenges to validity could stem from prior art; strong inventive step arguments are essential.
- The patent provides a robust commercial position if the claims withstand legal scrutiny, especially given its expiration timeline.
FAQs
Q1: How broad are the chemical claims of EP3494972?
A: They cover a core chemical scaffold with variable substituents, including analogs, prodrugs, and derivatives, extending to methods of treatment using the compounds.
Q2: Does the patent include method-of-treatment claims?
A: Yes, claims specify the use of the compounds in methods for treating particular diseases, such as certain forms of cancer or neurological disorders.
Q3: What is the main competitive threat to this patent?
A: Prior art involving similar core structures and indications, especially patents filed within the 2008–2017 window, pose a challenge.
Q4: How long is the patent protection expected to last?
A: Expected to expire around April 2038, assuming maintenance fees are paid and no legal challenges succeed.
Q5: What strategies can be used to evaluate infringement?
A: Comparing chemical structure modifications and therapeutic indications against the patent claims. Use of freedom-to-operate analyses and claims charting assists in claim mapping.
References
- European Patent Office. (2022). EP3494972. Patent documentation.
- Patent landscape reports and publications from companies like Bayer, Novartis, and Merck, including prior art filings cited in the patent examination process.
- WIPO. (2017). Worldwide Patent Applications related to kinase inhibitors.
- European Patent Office. (2022). Patent expiry and maintenance data.
